- Published at
- by zacks.com
positive
positive
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.
News for Bio-Techne Corporation (TECH)
- Published at
- by benzinga.com
mixedmixedThis Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - CervoMed (NASDAQ:CRVO), Qiagen (NYSE:QGEN)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...- Published at
- by gurufocus.com
positivepositiveBio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System
PR NewswireMINNEAPOLIS, Feb. 18, 2025 MINNEAPOLIS, Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative li- Published at
- by seekingalpha.com
positivepositiveBio-Techne signals high single-digit growth recovery by Q4 2025, driven by biopharma momentum (NASDAQ:TECH)
Earnings Call Insights: Bio-Techne Corporation (NASDAQ:TECH) Q2 2025Management ViewCEO Kim Kelderman highlighted 9% organic revenue growth for the quarter,...- Published at
- by seekingalpha.com
positivepositiveBio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Conference Call February 5, 2025 9:00 AM ETCompany ParticipantsDavid Clair - Vice President-Investor...- Published at
- by zacks.com
positivepositiveBio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.- Published at
- by seekingalpha.com
positivepositiveBio-Techne stock spikes on Q2 FY25 beat (TECH:NASDAQ)
Bio-Techne Corporation (TECH) stock climbs as its Q2 FY25 results exceed Wall Street estimates amid recovery in the biopharma end market. Read more here.- Published at
- by seekingalpha.com
neutralneutralBio-Techne declares $0.08 dividend (NASDAQ:TECH)
Bio-Techne (TECH) maintains $0.08/share quarterly dividend, with a forward yield of 0.44%. Dividend payable Feb. 28 for shareholders of record Feb.- Published at
- by gurufocus.com
positivepositiveBio-Techne Corp (TECH) Supports BrainChild Bio with $300,000 G-Rex® Grant
Bio-Techne Corp (TECH), in collaboration with ScaleReady, Wilson Wolf Manufacturing, and CellReady, announced on January 21, 2025, that BrainChild Bio has been- Published at
- by gurufocus.com
positivepositiveBio-Techne to Host Conference Call on February 5, 2025, to Announce Second Quarter Fiscal 2025 Financial Results
PR NewswireMINNEAPOLIS, Jan. 21, 2025 MINNEAPOLIS, Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will- Published at
- by gurufocus.com
positivepositiveBIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC
PR NewswireMINNEAPOLIS, Jan. 7, 2025 MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a- Published at
- by zacks.com
positivepositiveBio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?
TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic characterization and development processes.- Published at
- by gurufocus.com
positivepositiveBIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY
PR NewswireMINNEAPOLIS, Dec. 12, 2024 MINNEAPOLIS, Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company prov- Published at
- by zacks.com
positivepositiveBio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?
TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay.- Published at
- by zacks.com
neutralneutralShould You Continue to Retain Bio-Techne Stock in Your Portfolio?
Bio-Techne's success with four growth verticals and expansion through acquisitions bode well.- Published at
- by gurufocus.com
positivepositiveBIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE
PR NewswireMINNEAPOLIS, Nov. 27, 2024 MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman,- Published at
- by gurufocus.com
positivepositiveGemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne
PR NewswireWEST SACRAMENTO, Calif., Nov. 25, 2024 WEST SACRAMENTO, Calif., Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading s- Published at
- by gurufocus.com
positivepositiveBIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES
PR NewswireMINNEAPOLIS, Nov. 20, 2024 MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company prov- Published at
- by investing.com
positivepositiveBIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH By Investing.com
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH- Published at
- by gurufocus.com
positivepositiveBio-Techne Corporation (TECH) Announces Executive Compensation Update
Bio-Techne Corporation (TECH) has announced a significant update regarding its executive compensation strategy. On October 30, 2024, the company's Compensatio